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Abstract
The association between oral bisphosphonate use and upper gastrointestinal cancer has
been controversial. Therefore, we examined the association with esophageal and gastric
cancer within the Kaiser Permanente, Northern California population. A total of 1,011 cases
of esophageal (squamous cell carcinoma and adenocarcinoma) and 1,923 cases of gastric
adenocarcinoma (cardia, non-cardia and other) diagnosed between 1997 and 2011 from
the Kaiser Permanente, Northern California cancer registry were matched to 49,886 and
93,747 controls, respectively. Oral bisphosphonate prescription fills at least one year prior
to the index date were extracted. Conditional logistic regression was used to calculate odds
ratios (OR) and 95% confidence intervals (95% CI) for the associations between prospec-
tively evaluated oral bisphosphonate use with incident esophageal and gastric cancer
diagnoses with adjustment for potential confounders. After adjustment for potential con-
founders, no significant associations were found for esophageal squamous cell carcinoma
(OR 0.88; 95% CI: 0.51, 1.52), esophageal adenocarcinoma (OR 0.68; 95% CI: 0.37, 1.24),
or gastric non-cardia adenocarcinoma (OR 0.83, 95% CI: 0.59, 1.18), but we observed an
adverse association with gastric cardia adenocarcinoma (OR 1.64; 95% CI: 1.07, 2.50). In
conclusion, we observed no association between oral bisphosphonate use and esophageal
cancer risk within a large community-based population. A significant association was
detected with gastric cardia and other adenocarcinoma risk, although this needs to be
replicated.
Introduction
Osteoporosis is an important global issue with the growing aging population. In the United
States, an estimated 9 million adults have osteoporosis and at least 48 million adults have an
increased risk of osteoporosis related to low bone mass [1]. Bisphosphonates, a class of drugs
which decrease osteoclast-mediated bone resorption, are often prescribed to prevent and treat
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osteoporosis [2]. When not taken as instructed (i.e., lying down within 30 minutes of taking
the medication), oral bisphosphonates can cause injury to the esophageal mucosa resulting in
complications such as bleeding or ulcerations [3, 4]. In 2009, a US Food and Drug Administra-
tion case report suggested an association between bisphosphonates and risk of esophageal can-
cer, potentially related to bisphosphonate induced esophageal mucosal injury [5].
Epidemiological studies of the association between bisphosphonates and upper gastrointes-
tinal cancer have been inconsistent and these studies have generally not considered histological
or site-specific information for esophageal or gastric cancer [6–16]. Therefore, using a case-
control design, we assessed the potential association between oral bisphosphonate use and
upper gastrointestinal cancer within a large population which had not been previously utilized
to assess this association. This dataset additionally included important information on cancer
histology in order to address histological and site specific associations with bisphosphonates.
Materials and Methods
Source population
Cases and controls were selected from adult members ( 18 years old) of the Kaiser Perma-
nente, Northern California health system from 1997 to 2011. Kaiser Permanente is California’s
largest non-profit health plan and currently has approximately 3.3 million members in north-
ern California who are generally representative of the general population in that region [17].
This study was approved by the Kaiser Permanente, Northern California Institutional Review
Board which waived the requirement for written informed consent. All patient data was anon-
ymized and de-identified and this study was considered not human subjects research by the
National Cancer Institute.
Case identification
We selected cases of invasive esophageal (ICD–10: C15) and gastric (ICD–10: C16) cancer
from the Kaiser Permanente, Northern California cancer registry and assigned the date of the
diagnosis as the index date. Cases had to be at least 18 years old and have at least 2 years of
membership in Kaiser Permanente, Northern California prior to diagnosis. We excluded
cases with a history of cancer prior to the index cancer (as indicated in the cancer registry or
ICD–9 V codes) or a history of Paget’s disease (ICD–9: 731.0). Using these criteria, we identi-
fied 1,011 cases of esophageal and 1,923 cases of gastric cancer. Since the etiology of the two
main histologic types of esophageal cancer differ, cases were further classified as esophageal
squamous cell carcinoma (ICD-O–3 histology: 8070, 8071, 8094) or adenocarcinoma
(ICD-O–3 histology: 8140, 8144, 8210, 8481, 8490). Similarly, gastric cancer cases were
divided by site which included gastric cardia (ICD-O–3 site: C16.0), non-cardia (ICD-O–3
site: C16.1, C16.2, C16.3, C16.4, C16.5, C16.6, C16.7), and other adenocarcinoma including
overlapping (ICD-O–3 site: C16.8) and unspecified (ICD-O–3 site: C16.9) sub-sites. All gas-
tric cancers were adenocarcinoma.
Control selection
Up to 50 controls from the Kaiser Permanente, Northern California database were matched
without replacement to each case on gender, age at time of index date (+/- 2 years), duration of
membership prior to index date (+/- 1 year), race, and region of residence. To be eligible, the
control had to be at least 18 years of age and a member of Kaiser Permanente, Northern Cali-
fornia at the index date for the matched case and membership for at least two years prior to the
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index date for the matched case. A total of 49,886 and 93,747 controls were identified for the
cases of esophageal and gastric cancer, respectively.
Oral bisphosphonate exposure assessment
Data on oral bisphosphonate prescription fills were collected prior to the index date for both
cases and controls from the Kaiser Permanente, Northern California database. We categorized
exposure to oral bisphosphonates as ever (at least one prescription fill at least one year prior to
the index date) versus never. Among participants exposed to bisphosphonates, we calculated
defined daily dose of bisphosphonate exposure prior to the index date and categorized this as
less than 12 months of exposures and 12 or more months of exposure [18].
Other covariates of interest
Data on other covariates prior to the index date were collected from the Kaiser Permanente,
Northern California database including demographic variables (age, sex, and race/ethnicity),
history of smoking and alcohol consumption, body mass index (BMI) and the Charlson
Comorbidity Index (CCI) [19]. Diagnoses for other comorbidities including Barrett’s esopha-
gus, dyspepsia, esophagitis, gastroesophageal reflux disease (GERD), and osteoporosis were
included if identified at least one year prior to the index date. We determined which partici-
pants had a prescription drug fill at least one year prior to the index date for proton pump
inhibitors (PPIs), H2-receptor antagonists, hormone replacement therapy (HRT), and non-ste-
roidal anti-inflammatory drugs (NSAIDs). A history of receiving an upper or lower endoscopy
at least one year prior to the index date was also ascertained. All participants had complete
data for all covariates with the exception of BMI (52% missing), so the BMI data were only
used in sensitivity analyses.
Statistical analysis
Primary analysis. We described the esophageal cancer cases by histologic type, gastric
cancer cases by site, and the combined controls. We calculated odds ratios (ORs) and 95% con-
fidence intervals (95% CIs) for the associations between oral bisphosphonate use and esoph-
ageal and gastric cancer using conditional logistic regression with adjustment for age, smoking
status, alcohol use, CCI, use of PPIs, NSAIDs, or H2-receptor antagonists, and history of
GERD, osteoporosis, or upper endoscopy. We tested for an interaction between bisphospho-
nate use and sex on the risk of esophageal and gastric cancer by breaking the matched pairs
and including interaction terms in an unconditional logistic regression model.
Secondary analyses. As a sensitivity analysis, we created conditional logistic regression
models within the population with valid BMI data and tested the effect of the inclusion of BMI
in model adjustment. We additionally created a model within participants who had no indica-
tion of GERD (no diagnosis of GERD or a prescription for H2-receptor antagonists or PPIs)
and a model within participants who had not received an upper endoscopy at least one year
prior to the index date. All analyses were conducted using SAS 9.3 and a two-sided p-value of
0.05 was considered statistically significant.
Results
Demographic characteristics of the esophageal cancer cases, gastric cancer cases, and controls
are presented in Table 1. As expected, esophageal squamous cell carcinoma cases were more
likely to have smoked tobacco (67.0%) and to have consumed alcohol (51.9%) than the esoph-
ageal cancer controls (39.3% and 23.2%, respectively).
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Exposure to oral bisphosphonates was similar for esophageal squamous cell carcinoma and
adenocarcinoma cases compared to their matched controls (4.2% and 1.9% versus 4.3% and
2.4%, respectively). Gastric cardia and other gastric adenocarcinoma cases tended to have a
non-significant increase to oral bisphosphonates (4.5% and 6.8% versus 2.9% and 4.2%, respec-
tively) while the non-cardia gastric adenocarcinoma cases did not have a higher prevalence of
exposure to bisphosphonates compared to their matched controls (4.4% versus 5.0%, Table 2).
Table 1. Descriptive characteristics of the esophageal and gastric cancer cases and controls from Kaiser Permanente, Northern California, 1997–
2011.
Esophageal cancer Gastric cancer
SCC Adenocarcinoma Control Cardia Non-Cardia Other Control
%/Mean (SD) %/Mean (SD) %/Mean (SD) %/Mean (SD) %/Mean (SD) %/Mean (SD) %/Mean (SD)
Number of participants 385 626 49,886 626 915 382 93,747
Ever oral bisphosphonates 4.2% 1.9% 3.1% 4.5% 4.4% 6.8% 4.2%
Deﬁned Daily Dose
Never 95.8% 98.1% 96.9% 95.5% 95.6% 93.2% 95.8%
< 12 months 2.3% 1.0% 1.1% 1.6% 1.3% 2.6% 1.5%
>= 12 months 1.8% 1.0% 2.0% 2.9% 3.1% 4.2% 2.7%
Age at index 68.7 (10.8) 66.5 (11.4) 67.2 (11.1) 66.0 (11.7) 68.9(13.1) 66.5 (13.6) 67.2 (12.7)
Female 36.6% 12.9% 22.1% 20.8% 42.6% 41.4% 35.5%
Race/ethnicity
Non-Hispanic white 57.7% 80.0% 72.3% 72.8% 34.4% 35.6% 48.2%
Non-Hispanic black 14.8% 1.4% 6.3% 3.5% 13.6% 13.6% 9.9%
Hispanic 9.4% 10.7% 10.1% 12.0% 27.2% 27.7% 22.2%
Other 17.9% 7.7% 11.0% 11.5% 24.7% 22.8% 19.5%
Missing 0.3% 0.2% 0.2% 0.2% 0.1% 0.3% 0.2%
Smoked tobacco (% yes) 67.0% 61.5% 39.3% 51.6% 44.9% 38.2% 35.0%
Consumed alcohol (% yes) 51.9% 35.5% 23.2% 28.0% 24.8% 22.3% 19.8%
Body mass index
Missing 55.6% 46.3% 49.5% 54.5% 52.3% 53.9% 53.8%
Underweight 1.0% 0.0% 0.1% 0.0% 0.2% 0.0% 0.1%
Normal weight 23.4% 12.3% 15.8% 11.5% 16.8% 17.8% 16.1%
Overweight 11.2% 15.8% 17.3% 13.7% 15.2% 14.1% 15.3%
Obese 8.8% 25.6% 17.4% 20.3% 15.4% 14.1% 14.7%
CCI 0.8 (1.9) 0.6 (1.6) 0.2 (0.8) 0.8 (1.9) 1.4 (2.3) 1.3 (2.4) 0.2 (0.8)
History of Barrett's esophagus 0.5% 9.1% 0.5% 2.2% 0.4% 0.3% 0.5%
History of dyspepsia 7.5% 6.9% 7.6% 6.5% 13.4% 12.3% 8.6%
History of esophagitis 3.4% 6.7% 2.3% 2.9% 2.3% 2.1% 2.1%
History of GERD 21.6% 34.7% 22.0% 24.3% 26.3% 20.4% 21.4%
History of osteoporosis 42.3% 49.0% 47.9% 44.1% 45.7% 42.7% 46.8%
Previous lower endoscopy 40.0% 43.8% 45.6% 41.1% 40.0% 35.9% 41.8%
Previous upper endoscopy 11.2% 10.4% 6.4% 5.8% 6.7% 7.6% 6.2%
Ever PPIs 22.3% 28.0% 18.9% 21.4% 24.7% 20.4% 18.5%
Ever H2-RAs 29.9% 39.8% 33.3% 32.3% 43.9% 36.4% 34.6%
Ever HRT 14.8% 7.5% 12.5% 10.1% 19.5% 16.8% 17.1%
Ever NSAIDs 66.0% 67.9% 69.7% 66.9% 67.0% 63.1% 70.3%
Abbreviations: Charlson Comorbidity Index (CCI), gastroesophageal reﬂux disease (GERD), proton pump inhibitors (PPIs), H2-receptor antagonists
(H2-RAs), hormone replacement therapy (HRT), non-steroidal anti-inﬂammatory drugs (NSAIDs), squamous cell carcinoma (SCC)
doi:10.1371/journal.pone.0140180.t001
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No association was detected between oral bisphosphonate use at least one year prior to the
index date for esophageal squamous cell carcinoma (adjusted OR 0.92; 95% CI: 0.53, 1.60) or
adenocarcinoma (adjusted OR 0.68; 95% CI: 0.37, 1.24). Similarly, no consistent association
was detected for duration of exposure to oral bisphosphonates with esophageal cancer. A posi-
tive association was detected between oral bisphosphonate use and gastric cardia (adjusted OR
1.67; 95% CI: 1.09, 2.56) and other gastric adenocarcinoma (adjusted OR 1.93; 95% CI: 1.22,
3.06), while no significant association was observed with non-cardia gastric adenocarcinoma
(adjusted OR 0.84; 95% CI: 0.59, 1.20). The associations with gastric cardia and other gastric
adenocarcinoma were slightly strengthened for participants who had been exposed to oral bis-
phosphonates for a year or more (Table 2). No interactions were detected between oral bis-
phosphonate use and sex on any cancer outcome (p> 0.05; results not shown).
Secondary analyses
When we restricted the analyses to participants with BMI data, the estimates with and without
adjustment for BMI were relatively unchanged (results not shown). Exclusion of participants
with a prior GERD diagnosis produced nonsignificant trends for positive associations for gas-
tric cardia (OR 1.95; 95% CI: 0.98, 3.89) and other gastric (OR 1.77; 95% CI: 0.86, 3.65) adeno-
carcinomas (results not shown). Restriction to participants without an upper endoscopy at
Table 2. Conditional logistic regression for the associations between oral bisphosphonates and esophageal or gastric cancer in Kaiser Perma-
nente, Northern California, 1997–2011.
Cases Controls Unadjusted OR Adjusted OR
Bisphosphonate use N (%) N (%) (95% CI) (95% CI)
Esophageal cancer
Squamous cell carcinoma Never 369 (95.8%) 18,024 (95.7%) Ref Ref
Ever 16 (4.2%) 808 (4.3%) 0.96 (0.56, 1.65) 0.92 (0.53, 1.60)
< 12 months 9 (2.3%) 289 (1.5%) 1.52 (0.76, 3.02) 1.27 (0.63, 2.58)
 12 months 7 (1.8%) 519 (2.8%) 0.65 (0.30, 1.41) 0.68 (0.31, 1.50)
Adenocarcinoma Never 614 (98.1%) 30,316 (97.6%) Ref Ref
Ever 12 (1.9%) 738 (2.4%) 0.79 (0.43, 1.43) 0.68 (0.37, 1.24)
< 12 months 6 (1.0%) 278 (0.9%) 1.05 (0.46, 2.40) 0.84 (0.36, 1.92)
 12 months 6 (1.0%) 460 (1.5%) 0.62 (0.27, 1.44) 0.57 (0.25, 1.32)
Gastric cancer
Cardia Never 598 (95.5%) 29,951 (97.1%) Ref Ref
Ever 28 (4.5%) 900 (2.9%) 1.61 (1.05, 2.45) 1.67 (1.09, 2.56)
< 12 months 10 (1.6%) 322 (1.0%) 1.64 (0.85, 3.15) 1.58 (0.81, 3.06)
 12 months 18 (2.9%) 578 (1.9%) 1.59 (0.95, 2.65) 1.73 (1.03, 2.90)
Non-cardia Never 875 (95.6%) 42,027 (95.0%) Ref Ref
Ever 40 (4.4%) 2,224 (5.0%) 0.85 (0.60, 1.20) 0.84 (0.59, 1.20)
< 12 months 12 (1.3%) 796 (1.8%) 0.72 (0.40, 1.29) 0.63 (0.34, 1.15)
 12 months 28 (3.1%) 1,428 (3.2%) 0.93 (0.62, 1.39) 0.99 (0.65, 1.48)
Other Never 356 (93.2%) 17,856 (95.8%) Ref Ref
Ever 26 (6.8%) 789 (4.2%) 1.81 (1.16, 2.84) 1.93 (1.22, 3.06)
< 12 months 10 (2.6%) 285 (1.5%) 1.94 (1.00, 3.77) 1.91 (0.95, 3.82)
 12 months 16 (4.2%) 504 (2.7%) 1.74 (1.01, 3.01) 1.94 (1.12, 3.38)
Cases and controls were matched on gender, age at time of index date (+/- 2 years), duration of membership prior to index date (+/- 1 year), race, and
region of residence. The adjusted conditional logistic regression models additionally adjusted for age, smoking, alcohol use, CCI, use of PPIs, NSAIDs, or
H2-Receptor antagonists, history of GERD or osteoporosis, and previous upper endoscopy.
doi:10.1371/journal.pone.0140180.t002
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least one year prior to index strengthened the association with gastric cardia cancer (OR 1.87;
95% CI: 1.20, 2.91), but did not materially change the other associations (results not shown).
Discussion
In this study of esophageal and gastric cancer cases and controls in a community-based pop-
ulation, we found little evidence for an association between oral bisphosphonate use and
esophageal squamous cell carcinoma, esophageal adenocarcinoma, or non-cardia gastric ade-
nocarcinoma. There was an adverse association between oral bisphosphonate use and gastric
cardia and other gastric adenocarcinomas, however, in the dose-response analysis consider-
ing length of exposure to oral bisphosphonates, even just a short exposure to bisphospho-
nates (less than 12 months) appeared to increase the risk of gastric cardia and other
adenocarcinomas, raising the question of biologic plausibility given that it is unlikely that
only one year of exposure would increase the risk of cancer. It is possible that the observed
association between gastric cardia and other gastric adenocarcinoma may be related to pre-
scribing behaviors of physicians. Within the controls, participants with a history of GERD or
a prescription for PPIs or H2-receptor antagonists were more likely to have received an oral
bisphosphonate (results not shown), so it is possible that participants at higher risk for gastric
cardia or other gastric cancers were more likely to have received a prescription for bisphos-
phonates leading to spurious associations, although, if this were the case, one would also
expect a higher risk of esophageal adenocarcinoma. Bisphosphonates may be associated with
gastric ulcers [20], which could potentially be a mechanism for this association, but since
there are also indications that bisphosphonates possess antitumor capabilities [21], this find-
ing would need to be replicated.
Previous work has been conflicting relating to the potential association between bisphos-
phonate use and the risk of esophageal and gastric cancer, but in general, a number of studies
support our null findings with esophageal and non-cardia gastric cancer with little support for
a positive association with gastric cardia and other gastric cancer risk. A matched cohort study
using the UK General Practice Research Database (GPRD) did not detect associations between
bisphosphonate use and esophageal cancer, nor an association with esophageal and gastric
cancer combined [8]. However, a nested case-control study also using the GPRD found an
increased risk of esophageal cancer, but not gastric cancer, with at least one bisphosphonate
prescription versus no prescriptions (OR 1.30; 95% CI: 1.02, 1.66) and a higher risk of esoph-
ageal cancer for longer durations of use [10]. The reason for the different findings in these two
studies is unclear but could reflect the differences in the time period studied, adjustment for
confounders, study design, or exclusion criteria. Two additional studies used the GPRD data-
base to address these differing results, again, with contrasting conclusions. In the first study, a
statistically significant association with esophageal (OR 1.43; 95% CI: 1.16, 1.75) and all upper
gastrointestinal cancers (OR 1.24; 95% CI: 1.06, 1.45) was observed for women and a significant
decreased risk of upper gastrointestinal cancer was observed for men (OR 0.75; 95% CI: 0.57,
0.98), but no association was detected with gastric cancer for men and women and with esoph-
ageal cancer for men [16]. However, a more recent study using the GPRD and another UK
database, QResearch, generally did not find an association between bisphosphonate use and
risk of esophageal or gastric cancer [15]. Two studies each were also published from Denmark
and Taiwan, with conflicting results. In Denmark, one study found an increased risk of esoph-
ageal cancer after treatment with alendronate (hazard ratio (HR) 2.10; 95% CI: 1.01, 4.35) and
with etidronate (HR 1.99; 95% CI: 1.24, 3.18), but no dose or time trends were observed [14].
The other Danish study detected a decreased risk of gastric (HR 0.61; 95% CI: 0.39, 0.97) and
gastric and esophageal cancer combined (HR 0.63; 95% CI: 0.45, 0.87) for alendronate users,
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but no association with esophageal cancer only [7]. This study also found that alendronate
users were significantly more likely to have undergone a recent upper endoscopy, which could
appear to increase the likelihood of diagnosis of esophageal cancer, but the mortality rate
would remain the same or be reduced since earlier diagnosis of esophageal cancer would lead
to an apparent increase in incidence but cases would be less likely to die due to the earlier diag-
nosis. In support of this, they found that the short term mortality risk (i.e., within 3 years of ini-
tiating alendronate treatment) was decreased for esophageal and gastric cancer [7]. In Taiwan,
one study did not detect a significant risk of esophageal cancer with bisphosphonate use [9],
while the other study found inverse trends for duration of use among rare and frequent users
of bisphosphonates compared to non-users and a non-significant positive trend among regular
users [11].
There are limitations to our study. The data on prescription drugs and comorbid conditions
were obtained from claims data which may not entirely cover each participant’s healthcare
experience. For prescription drugs, including oral bisphosphonates, there is no information on
adherence or whether participants took the medication according to instructions. However,
since these are filled prescriptions, it is unlikely that participants continued filling the prescrip-
tion if they were not taking them. Similarly, any bisphosphonate use from another insurance
provider would not be included so the total duration of exposure may be underestimated.
Comorbid conditions may also be underestimated since they require a physician’s diagnosis in
the time period of study. This study only included participants with comprehensive health
insurance coverage and therefore, may not be representative of the uninsured or underinsured;
however, this population is generally representative of the region of coverage [17]. Finally,
residual confounding by unmeasured covariates may be present. For example, we did not have
information related to Helicobacter pylori seropositivity, which is an important risk factor for
gastric cancer. However, although we excluded BMI, a potential confounder, from the primary
analyses due to a high proportion of missing data, when we conducted the analyses within the
population with valid BMI data, no residual confounding was generally detected. Although we
included information on sub-site and histology, we were unable to characterize the tumors
using molecular pathological epidemiologic classifications as has been suggested in some recent
publications [22–26]. Future studies may wish to consider these molecular pathological classifi-
cations, if possible.
This study also has a number of strengths. This data represents a large number of cases and
controls from a comprehensive healthcare system. Almost all enrollees of Kaiser Permanente,
Northern California receive all health care through this health plan, so it is unlikely that miss-
ing utilization or prescription data substantially biased the results. All of the cancer diagnoses
were obtained from the Kaiser Permanente, Northern California cancer registry which is a
well-established registry with>98% capture of cancer diagnoses compared with validation
studies. In addition, we were able to consider histological and site-specific information which
few previous studies have considered. Also, since undiagnosed upper gastrointestinal cancer
may lead to increased diagnoses of related conditions and new medication uptake and recent
initiation of a prescription medication is unlikely to contribute to cancer development, we
excluded diagnoses and prescription medications which were first observed in the year prior to
the index date.
In conclusion, we did not observe an association between oral bisphosphonate use and
esophageal cancer risk within a large community-based population. A significant association
was detected with gastric cardia and other gastric adenocarcinoma risk, but this needs to be
replicated since no previous studies detected an adverse association with gastric cancer. Future
research should include detailed histological and site specific information to further ascertain
these possible associations.
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